Mark Bounthavong1,2,3,4, Emily Beth Devine2,5, Melissa L D Christopher1, Michael A Harvey1, David L Veenstra2, Anirban Basu2,5. 1. Pharmacy Benefits Management (PBM), National Academic Detailing Service, U.S. Department of Veterans Affairs, Washington, DC. 2. The Comparative Health Outcomes, Policy, & Economics (CHOICE) Institute, University of Washington, Seattle, Washington. 3. Veterans Affairs (VA) Health Economics Resource Center (HERC), Menlo Park, California. 4. Veterans Affairs (VA) Center for Innovation to Implementation (Ci2i), Menlo Park, California. 5. Department of Health Services, School of Public Health, University of Washington, Seattle, Washington.
Abstract
OBJECTIVE: Academic detailing in partnership with the Opioid Overdose Education and Naloxone Distribution (OEND) program was implemented to increase naloxone access for the prevention of opioid overdose mortality in veterans at the U.S. Department of Veterans Affairs (VA). However, implementation was not uniform leading to varying levels of intervention exposure potentially impacting naloxone prescribing. We examined the impact of implementation strength (proportion of providers exposed to academic detailing) at each station on naloxone prescribing from September 2014 to December 2017. STUDY DESIGN AND SETTING: Retrospective cohort design with fixed effects models at the VA. DATA COLLECTION/EXTRACTION METHODS: We used VA Corporate Data Warehouse for data on pharmacy dispensing, station-, provider- and patient-level characteristics. OEND-specific academic detailing activities came from data recorded by academic detailers using Salesforce.com. PRINCIPAL FINDINGS: VA stations wherein 100 percent of providers exposed to an OEND-related academic detailing educational outreach visit experienced an increased incident rate of naloxone prescribing that was 5.52 times the incident rate of stations where no providers were exposed; alternatively, this is equivalent to an average monthly increase of 2.60 naloxone prescriptions per 1000 population at risk for opioid overdose. CONCLUSIONS: Our findings highlight the importance of academic detailing's implementation strength on naloxone prescribing. Decision makers must carefully consider the implementation process to achieve the greatest effectiveness from the intervention.
OBJECTIVE: Academic detailing in partnership with the Opioid Overdose Education and Naloxone Distribution (OEND) program was implemented to increase naloxone access for the prevention of opioid overdose mortality in veterans at the U.S. Department of Veterans Affairs (VA). However, implementation was not uniform leading to varying levels of intervention exposure potentially impacting naloxone prescribing. We examined the impact of implementation strength (proportion of providers exposed to academic detailing) at each station on naloxone prescribing from September 2014 to December 2017. STUDY DESIGN AND SETTING: Retrospective cohort design with fixed effects models at the VA. DATA COLLECTION/EXTRACTION METHODS: We used VA Corporate Data Warehouse for data on pharmacy dispensing, station-, provider- and patient-level characteristics. OEND-specific academic detailing activities came from data recorded by academic detailers using Salesforce.com. PRINCIPAL FINDINGS: VA stations wherein 100 percent of providers exposed to an OEND-related academic detailing educational outreach visit experienced an increased incident rate of naloxone prescribing that was 5.52 times the incident rate of stations where no providers were exposed; alternatively, this is equivalent to an average monthly increase of 2.60 naloxone prescriptions per 1000 population at risk for opioid overdose. CONCLUSIONS: Our findings highlight the importance of academic detailing's implementation strength on naloxone prescribing. Decision makers must carefully consider the implementation process to achieve the greatest effectiveness from the intervention.
Authors: Elizabeth M Oliva; Melissa L D Christopher; Daina Wells; Mark Bounthavong; Michael Harvey; Julianne Himstreet; Thomas Emmendorfer; Michael Valentino; Mariano Franchi; Francine Goodman; Jodie A Trafton Journal: J Am Pharm Assoc (2003) Date: 2017 Mar - Apr
Authors: Phillip O Coffin; Emily Behar; Christopher Rowe; Glenn-Milo Santos; Diana Coffa; Matthew Bald; Eric Vittinghoff Journal: Ann Intern Med Date: 2016-06-28 Impact factor: 25.391
Authors: Mark Bounthavong; Emily Beth Devine; Melissa L D Christopher; Michael A Harvey; David L Veenstra; Anirban Basu Journal: Health Serv Res Date: 2019-07-17 Impact factor: 3.402
Authors: Carlos Blanco; Mir M Ali; Aaron Beswick; Karen Drexler; Cheri Hoffman; Christopher M Jones; Tisha R A Wiley; Allan Coukell Journal: NAM Perspect Date: 2020-10-26
Authors: Shari S Rogal; Matthew Chinman; Walid F Gellad; Maria K Mor; Hongwei Zhang; Sharon A McCarthy; Genna T Mauro; Jennifer A Hale; Eleanor T Lewis; Elizabeth M Oliva; Jodie A Trafton; Vera Yakovchenko; Adam J Gordon; Leslie R M Hausmann Journal: Implement Sci Date: 2020-06-23 Impact factor: 7.327
Authors: Toni Marie Rudisill; Alexandria J Ashraf; Herbert I Linn; Sheena Sayres; James E Jeffries; Kelly K Gurka Journal: Inj Prev Date: 2020-09-01 Impact factor: 3.770
Authors: Jonathan D Hoffman; Ramona Shayegani; Patrick M Spoutz; Ashley D Hillman; Jason P Smith; Daina L Wells; Sarah J Popish; Julianne E Himstreet; Jane M Manning; Mark Bounthavong; Melissa L D Christopher Journal: J Am Pharm Assoc (2003) Date: 2020-07-31